This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ASM journals
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Satoh, M.
Right arrow Articles by Yoshida, O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Satoh, M.
Right arrow Articles by Yoshida, O.

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1992 July; 36(7): 1580-1583
Copyright © 1992, American Society for Microbiology. All Rights Reserved.

Evaluation of the Usefulness of a Novel Injectable Cephalosporin, E1040, and Ceftazidime for Management of Complicated Urinary Tract Infections Caused by Pseudomonas aeruginosa and Proteus mirabilis by Using the Rat Urolithiasis Model

Masaru Satoh*, Kei-Ichi Munakata, Hideo Takeuchi and Osamu Yoshida

1 Department of Microbiology, Tokyo Research Laboratories, Eisai Co., Ltd., 4 Koishikawa, Bunkyo-ku, Tokyo 112, and Department of Urology, Faculty of Medicine, Kyoto University, 54 Kawara-machi, Shogoin, Sakyo-ku, Kyoto 606,2 Japan

ABSTRACT

A novel injectable cephalosporin, E1040, significantly eradicated Pseudomonas aeruginosa from the urine, in contrast to ceftazidime, in rats with complicated P. aeruginosa urinary tract infections associated with urinary stones, suggesting that E1040 is a prospective therapeutic agent in the management of refractory Pseudomonas urinary tract infections.


FOOTNOTES

* Corresponding author.


Antimicrob Agents Chemother. 1992 July; 36(7): 1580-1583
Copyright © 1992, American Society for Microbiology. All Rights Reserved.